Effects of (R)-9-(2-phosphonylmethoxypropyl)adenine monotherapy on chronic SIV infection in macaques

AIDS Research and Human Retroviruses

Volumn 13, Issue 8, 1997, Pages 707-712

  Tsai, Che Chung ^a,e   Follis, Kathryn E ^a,b   Beck, Thomas W ^a   Sabo, Alexander ^a   Bischofberger, Norbert ^c   Dailey, Peter J ^d  

^a Regional Primate Research Centre   (United States)

^b UNIVERSITY OF MONTANA   (United States)

^c GILEAD SCIENCES   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CHRONIC DISEASE; DRUG EFFICACY; MACACA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROVIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS INFECTION; VIRUS INHIBITION;

EID: 0030955396     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.707     Document Type: Article

References (25)

1. Richman DD: Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993;37:1207-1213.
2. Larder BA: Viral resistance and the selection of antiretroviral combinations. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(Suppl. 1):S28-S33.
3. Wyand MS: The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines. AIDS Res Hum Retroviruses 1992;8:349-356.
4. McClure HM, Anderson DC, Ansari AA, Fultz PN, Klumpp SA, and Schinazi RF: Nonhuman primate models for evaluation of AIDS therapy. Ann NY Acad Sci 1990;616:287-298.
5. Lundgren B, Böttiger D, Ljungdahl-Stahle E, Norrby E, Stahle L, Wahren B, and Öberg B: Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr 1991;4:489-498.
6. Fazely F, Haseltine WA, Rodger RF, and Ruprecht RM: Post-exposure chemoprophylaxis with ZDV or ZDV combined with interferon-α: Failure after inoculating rhesus monkeys with a high dose of SIV. J Acquir Immune Defic Syndr 1991;4:1093-1097.
7. Martin LN, Murphey-Corb M, Soike KF, Davison-Fairburn B, and Baskin GB: Effects of initiation of 3′-azido-3′-deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis 1993;168:825-835.
8. Tsai C-C, Follis KE, Grant RF, Nolte RE, Bartz CR, Benveniste RE, and Sager PR: Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr 1993;6:1086-1092.
9. LeGrand M, Clayette P, Noack O, Vaslin B, Theodora F, Michel G, Roques P, and Dormont D: An animal model for antilentiviral therapy: Effect of zidovudine on viral load during acute infection after exposure of macaques to simian immunodeficiency virus. AIDS Res Hum Retroviruses 1994;10:1279-1287.
10. Van Rompay KKA, Otsyula MG, Marthas ML, Miller CJ, McChesney MB, and Pedersen NC: Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 1995;39:125-131.
11. De Clercq E, Holy A, Rosenberg I, Sakuma T, Balzarini J, and Maudgal PC: A novel selective broad-spectrum anti-DNA virus agent. Nature (London) 1986;323:464-467.
12. Balzarini J, Naesens L, Slachmuylders J, Niphuis H, Rosenberg I, Holy A, Schellekens H, and De Clercq E: 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 1991;5:21-28.
13. Balzarini J, Holy A, Jindrich J, Naesens L, Snoeck R, Schols D, and De Clercq E: Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 1993;37:332-338.
14. Tsai C-C, Follis KE, Sabo A, Grant RF, Bartz C, Nolte RF, Benveniste RE, and Bischofberger N: Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J Infect Dis 1994;169:260-266.
15. Tsai C-C, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, Benveniste RE, and Black R: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 1995;270:1197-1199.
16. Tsai C-C, Follis KE, Yarnall M, Deaver LE, Benveniste RE, and Sager PR: In vitro screening for antiretroviral agents against simian immunodeficiency virus (SIV). Antivirol Res 1990;14:87-98.
17. Dailey PJ, Zamroud M, Kelso R, Kolberg J, and Urdea M: Quantitation of simian immunodeficiency virus (SIV) RNA in plasma of acute and chronically infected macaques using a branched DNA (bDNA) signal amplification assay. J Med Primatol 1995;24:209.
18. Pachl C, Todd JA, Kern DG, Sheridan PJ, Fong SJ, Stempien M, Hoo B, Besemer D, Yeghiazarian T, and Irvine B: Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol 1995;8:446-454.
19. Van Rompay KKA, Marthas ML, Ramos RA, Mandell CP, McGowan EK, Joye SM, and Pedersen NC: Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy; oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother 1992;36:2381-2386.
20. Tsai C-C, Follis KE, Sabo A, Grant R, and Bischofberger N: Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J Infect Dis 1995;171:1338-1343.
21. Caliendo AM and Hirsch MS: Combination therapy for infection due to human immunodeficiency virus type 1. Clin Infect Dis 1994;18:516-524.
22. Hammer SM: Advances in antiretroviral therapy and viral load monitoring. AIDS 1996;10(Suppl. 3):S1-S11.
23. Vella S: HIV pathogenesis and treatment strategies. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(Suppl. 1):S20-S23.
24. Lange JMA: Triple combinations: Present and future. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(Suppl. 1):S77-S82.
25. Richman DD: HIV therapeutics. Science 1996;272:1886-1888.